Perspective Therapeutics, Inc. (CATX)
3.11
-0.07
(-2.20%)
USD |
NYAM |
Aug 28, 16:00
3.095
-0.02
(-0.48%)
After-Hours: 20:00
Perspective Therapeutics Free Cash Flow : -121.38M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -121.38M |
| March 31, 2026 | -107.53M |
| December 31, 2025 | -95.45M |
| September 30, 2025 | -106.85M |
| June 30, 2025 | -114.90M |
| March 31, 2025 | -103.80M |
| December 31, 2024 | -72.78M |
| September 30, 2024 | |
| June 30, 2024 | |
| March 31, 2024 | |
| September 30, 2023 | -31.92M |
| June 30, 2023 | -23.03M |
| March 31, 2023 | -15.78M |
| June 30, 2022 | -7.994M |
| March 31, 2022 | -6.236M |
| December 31, 2021 | -5.509M |
| September 30, 2021 | -4.935M |
| June 30, 2021 | -3.248M |
| March 31, 2021 | -2.879M |
| December 31, 2020 | -3.064M |
| September 30, 2020 | -3.628M |
| June 30, 2020 | -3.928M |
| March 31, 2020 | -4.117M |
| December 31, 2019 | -4.677M |
| September 30, 2019 | -4.518M |
| Date | Value |
|---|---|
| June 30, 2019 | -5.493M |
| March 31, 2019 | -5.989M |
| December 31, 2018 | -5.684M |
| September 30, 2018 | -6.078M |
| June 30, 2018 | -6.067M |
| March 31, 2018 | -5.937M |
| December 31, 2017 | -6.315M |
| September 30, 2017 | -6.449M |
| June 30, 2017 | -6.385M |
| March 31, 2017 | -6.380M |
| December 31, 2016 | -5.809M |
| September 30, 2016 | -4.897M |
| June 30, 2016 | -4.376M |
| March 31, 2016 | -3.627M |
| December 31, 2015 | -3.836M |
| September 30, 2015 | -3.650M |
| June 30, 2015 | -3.673M |
| March 31, 2015 | -3.989M |
| December 31, 2014 | -3.320M |
| September 30, 2014 | -3.521M |
| June 30, 2014 | -3.265M |
| March 31, 2014 | -3.047M |
| December 31, 2013 | -3.297M |
| September 30, 2013 | -3.020M |
| June 30, 2013 | -3.069M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Anika Therapeutics, Inc. | 0.562M |
| MiMedx Group, Inc. | 42.33M |
| ABVC BioPharma, Inc. | -2.697M |
| Enovis Corp. | 63.66M |
| Edwards Lifesciences Corp. | 1.434B |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -20.65M |
| Cash from Investing (Quarterly) | 15.02M |
| Cash from Financing (Quarterly) | 0.147M |
| Free Cash Flow Per Share (Quarterly) | -0.289 |
| Free Cash Flow to Equity (Quarterly) | -34.60M |
| Free Cash Flow to Firm (Quarterly) | -34.80M |
| Free Cash Flow Yield | -41.87% |